Cinctive Capital Management LP Sells 51,362 Shares of Annexon, Inc. (NASDAQ:ANNX)

Cinctive Capital Management LP lessened its stake in shares of Annexon, Inc. (NASDAQ:ANNX) by 27.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 135,466 shares of the company’s stock after selling 51,362 shares during the quarter. Cinctive Capital Management LP owned approximately 0.13% of Annexon worth $695,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. FMR LLC boosted its position in Annexon by 3.2% during the 3rd quarter. FMR LLC now owns 8,561,949 shares of the company’s stock valued at $50,687,000 after buying an additional 262,229 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Annexon by 11.6% during the fourth quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock worth $28,456,000 after purchasing an additional 576,625 shares during the period. State Street Corp boosted its holdings in shares of Annexon by 116.6% during the third quarter. State Street Corp now owns 3,841,879 shares of the company’s stock worth $22,744,000 after purchasing an additional 2,068,294 shares during the period. Candriam S.C.A. grew its stake in shares of Annexon by 15.6% in the fourth quarter. Candriam S.C.A. now owns 2,534,230 shares of the company’s stock worth $13,001,000 after purchasing an additional 341,431 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Annexon by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 2,171,478 shares of the company’s stock valued at $11,142,000 after purchasing an additional 27,843 shares during the period.

Annexon Trading Down 6.6 %

Shares of ANNX stock opened at $1.83 on Friday. The company’s fifty day moving average price is $2.86 and its 200-day moving average price is $4.86. The stock has a market cap of $200.77 million, a PE ratio of -1.74 and a beta of 1.24. Annexon, Inc. has a 12 month low of $1.73 and a 12 month high of $7.85.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, sell-side analysts forecast that Annexon, Inc. will post -0.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Annexon in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Annexon in a report on Tuesday, December 17th.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.